Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$21 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-4 Mln
ROE
-0.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.9
Industry P/E
24.51
EV/EBITDA
0
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
21,003,400
CFO
$-248.83 Mln
EBITDA
$-270.69 Mln
Net Profit
$-251.73 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Onconova Therapeutics (ONTX)
| -14.5 | -35.8 | -10.5 | -43.2 | -61.0 | -60.0 | -62.9 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Onconova Therapeutics (ONTX)
| 16.2 | -74.5 | -63.5 | 21.6 | -81.8 | -90.5 | -33.9 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase... inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. Read more
CEO, President & Director
Dr. Steven M. Fruchtman M.D.
CEO, President & Director
Dr. Steven M. Fruchtman M.D.
Headquarters
Newtown, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Onconova Therapeutics Inc (ONTX) is $0.64 (NASDAQ) as of 02-May-2024 09:30 EDT. Onconova Therapeutics Inc (ONTX) has given a return of -60.97% in the last 3 years.
Since, TTM earnings of Onconova Therapeutics Inc (ONTX) is negative, P/E ratio is not available.
The P/B ratio of Onconova Therapeutics Inc (ONTX) is 1.86 times as on 02-May-2024, a 67 discount to its peers’ median range of 5.66 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
The 52-week high and low of Onconova Therapeutics Inc (ONTX) are Rs -- and Rs -- as of 03-Apr-2026.
Onconova Therapeutics Inc (ONTX) has a market capitalisation of $ 21 Mln as on 02-May-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Onconova Therapeutics Inc (ONTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-7.29
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.